How India Exports Budesonide to the World

In the United States, budesonide is approved by the Food and Drug Administration (FDA) for various formulations, including inhalation suspensions and inhalers. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for budesonide products, indicating a competitive generic market. Notably, on November 16, 2017, the FDA approved Cipla's generic version of Pulmicort Respules (budesonide inhalation suspension) in strengths of 0.25 mg/2 mL and 0.5 mg/2 mL. This approval underscores the significant role of Indian pharmaceutical companies in supplying budesonide to the U.S. market. The absence of current FDA import alerts related to budesonide suggests compliance with regulatory standards by Indian exporters.

Within the European Union (EU) and the United Kingdom (UK), budesonide-containing products require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA). For instance, the EMA granted marketing authorization for Budesonide/Formoterol Teva on November 19, 2014; however, this authorization was withdrawn on December 16, 2016, at the request of the marketing authorization holder for commercial reasons. (ema.europa.eu) This highlights the dynamic nature of the regulatory landscape in the EU. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to these regions, ensuring product quality and safety.

Budesonide is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating priority health conditions. The 24th edition of the WHO Model List, published on September 5, 2025, continues to list budesonide as an essential medicine. (who.int) This inclusion reflects its recognized efficacy and safety profile. Additionally, budesonide formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, budesonide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of the latest updates, budesonide is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring compliance with export regulations.

The primary patents for budesonide formulations have expired, leading to increased generic competition globally. This has facilitated the entry of multiple manufacturers into the market, enhancing accessibility and affordability of budesonide-containing products.

In April 2025, the WHO unveiled a global repository for National Essential Medicines Lists (nEMLs), aiming to harmonize and improve access to essential medicines, including budesonide. (who.int) This initiative is expected to streamline procurement processes and ensure consistent availability of essential medicines worldwide.

In February 2025, the WHO published a feature story highlighting the expansion of biosimilars, including those for essential biologic therapies. (who.int) This development is pertinent to the budesonide market, as biosimilar competition can influence pricing and availability.

In March 2025, the WHO announced the opening of the application period for the 2025 update of the WHO Model Lists of Essential Medicines. (who.int) This process allows for the inclusion of new medicines and the reevaluation of existing ones, potentially impacting the status of budesonide on the list.

In May 2025, the WHO's 25th Expert Committee on Selection and Use of Essential Medicines convened to review and update the Model List of Essential Medicines. (who.int) The outcomes of this meeting may influence the global positioning and utilization of budesonide in treatment protocols.

In February 2026, the WHO published the Department of Regulation and Prequalification 2025 annual report, detailing regulatory advancements and prequalification activities that impact the approval and distribution of medicines like budesonide. (who.int) This report provides insights into the evolving regulatory landscape affecting pharmaceutical exports.

These developments underscore the dynamic nature of the pharmaceutical industry and the importance of staying informed about regulatory changes and market trends affecting budesonide exports from India.

India's pharmaceutical industry, including the production of Budesonide, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese suppliers, underscoring a significant dependency on external sources for critical raw materials. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese exports can lead to shortages and increased costs for Indian manufacturers.

The COVID-19 pandemic highlighted these risks when Chinese factory shutdowns caused immediate scarcities of essential APIs, leading to price surges and production delays in India. In response, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024, aiming to bolster domestic production of APIs and KSMs. This initiative led to the inauguration of two greenfield plants dedicated to manufacturing critical molecules like Penicillin G and Clavulanic Acid, which are vital for common antibiotics. Despite these efforts, the transition to self-sufficiency is gradual, and the industry remains susceptible to external supply chain disruptions.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in Budesonide exports from India. The top five exporters account for 94.8% of the total export value, with CIPLA LIMITED alone contributing 87.8% ($167.3 million USD). This significant concentration indicates a potential single-source risk, where disruptions affecting leading suppliers could have a disproportionate impact on the global availability of Budesonide.

The PLI scheme, launched in October 2024, aims to mitigate such risks by encouraging diversification and enhancing domestic production capabilities. While this initiative has led to the establishment of new manufacturing units, the benefits are expected to materialize over the medium to long term. In the interim, the high supplier concentration continues to pose a risk to supply chain stability.

Recent geopolitical events have further strained the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz following military conflicts disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Such disruptions can cascade through the pharmaceutical supply chain, affecting the availability of essential drugs like Budesonide.

Additionally, tensions in the Red Sea and the Strait of Hormuz have led to increased shipping costs and delays, impacting the timely delivery of pharmaceutical products. The U.S. Food and Drug Administration (FDA) has acknowledged these challenges, emphasizing the need for a resilient supply chain to prevent drug shortages. These geopolitical factors underscore the importance of diversifying supply sources and enhancing domestic production to mitigate risks associated with international conflicts and shipping disruptions.

• Diversify Supplier Base: Encourage the development of multiple suppliers for Budesonide to reduce dependency on a single source and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme to boost domestic manufacturing of APIs and KSMs, reducing reliance on imports.

• Enhance Supply Chain Transparency: Implement robust monitoring systems to track the origin and movement of raw materials and finished products, enabling proactive risk management.

• Develop Strategic Reserves: Establish reserves of critical APIs and KSMs to buffer against short-term supply disruptions caused by geopolitical events or natural disasters.

• Foster International Collaboration: Engage in partnerships with other countries to create a more diversified and secure global supply chain for pharmaceutical products.

RISK_LEVEL: HIGH